MacroGenicsMGNX
Market Cap: $212M
About: Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).
Employees: 339
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
13% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 47
7.11% less ownership
Funds ownership: 104.17% [Q1] → 97.06% (-7.11%) [Q2]
12% less funds holding
Funds holding: 163 [Q1] → 144 (-19) [Q2]
42% less call options, than puts
Call options by funds: $1.14M | Put options by funds: $1.97M
43% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 44
73% less capital invested
Capital invested by funds: $957M [Q1] → $258M (-$698M) [Q2]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
HC Wainwright & Co. Robert Burns 46% 1-year accuracy 66 / 145 met price target | 18%upside $4 | Neutral Reiterated | 18 Sept 2024 |
HC Wainwright & Co. Robert Burns 46% 1-year accuracy 66 / 145 met price target | 18%upside $4 | Neutral Reiterated | 21 Aug 2024 |
Citigroup Yigal Nochomovitz 45% 1-year accuracy 17 / 38 met price target | 313%upside $14 | Buy Maintained | 15 Aug 2024 |
BMO Capital Etzer Darout 61% 1-year accuracy 19 / 31 met price target | 47%upside $5 | Market Perform Maintained | 7 Aug 2024 |
HC Wainwright & Co. Robert Burns 46% 1-year accuracy 66 / 145 met price target | 18%upside $4 | Neutral Reiterated | 1 Aug 2024 |
Financial journalist opinion
Based on 299 articles about MGNX published over the past 30 days